BG
KYNB

Bellevue Group’s Kyntra Bio KYNB Stock Holding History

Bellevue Group’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,400
Closed -$2.08M – 219
2021
Q1 		$2.08M Buy
2,400
+280
+13% +$298K 0.02% 141
2020
Q4 		$1.97M Hold
2,120
– – 0.02% 145
2020
Q3 		$2.18M Buy
+2,120
New +$2.28M 0.03% 143
2020
Q2 		– Sell
-1,504
Closed -$1.31M – 214
2020
Q1 		$1.31M Sell
1,504
-36
-2% -$35.8K 0.03% 138
2019
Q4 		$1.65M Buy
+1,540
New +$1.57M 0.03% 135
2019
Q2 		– Sell
-1,952
Closed -$2.65M – 206
2019
Q1 		$2.65M Buy
1,952
+672
+53% +$911K 0.15% 98
2018
Q4 		$1.48M Buy
+1,280
New +$1.44M 0.1% 103

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group's KYNB Position: Q2 2021 in Review

Bellevue Group sold out of Kyntra Bio (KYNB) in Q2 2021, closing a stake of 2,400 shares — an estimated $2.08M sold.

Bellevue Group first reported a position in KYNB in Q4 2018 and held it in 7 quarters. The position peaked at $2.65M in Q1 2019. 174 funds tracked by Wall St. Rank hold KYNB as of Q2 2021.

  • Bellevue Group reported no remaining Kyntra Bio position as of Q2 2021 after selling out during the quarter.
  • Bellevue Group sold 2,400 Kyntra Bio shares in Q2 2021, an estimated $2.08M.
  • Bellevue Group first reported a position in Kyntra Bio in Q4 2018 and held it in 7 quarters.
  • Bellevue Group's Kyntra Bio position peaked at $2.65M in Q1 2019.
  • 174 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2021.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.